Arcturus Therapeutics (ARCT) Price & Analysis

Compare

1,786 Followers

ARCT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$8.04 - $25.88

Previous CloseN/A

Volume109.32K

Average Volume (3M)414.18K

Market Cap

$323.01M

Enterprise Value$74.27M

Total Cash (Recent Filing)$216.95M

Total Debt (Recent Filing)$42.66M

Price to Earnings (P/E)―

Beta2.31

Next Earnings

Nov 05, 2025

EPS Estimate

-0.85

Last Dividend Ex-Date

Jan 08, 2013

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.34

Shares Outstanding27,120,604

10 Day Avg. Volume388,806

30 Day Avg. Volume414,178

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.23

Enterprise Value/Revenue0.55

Enterprise Value/Gross Profit0.54

Enterprise Value/Ebitda-1.23

Forecast

1Y Price Target

$56.14

Price Target Upside392.89% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Cystic Fibrosis ProgramThe company is poised to potentially become the first approved mRNA therapy for class I/modulator non-responsive CF patients.

Vaccine TechnologyARCT's vaccine platform, based on self-amplifying RNA technology, has shown superior results compared to PFE/BNTX's Comirnaty in a head-to-head comparison.

Bears Say

Investment SentimentThe winding down of BARDA investment in mRNA-based vaccines is a disappointing update for mRNA sentiment broadly.

Regulatory ChallengesDefinite limitations of the current data set (small N, differing protocols) and uncertainty on the regulatory path.

Arcturus Therapeutics News

Arcturus Therapeutics price target raised to $49 from $47 at Citi

Citi raised the firm’s price target on Arcturus Therapeutics (ARCT) to $49 from $47 and keeps a Buy...

10h ago

ARCT

Arcturus Therapeutics price target lowered to $42 from $45 at Wells Fargo

Wells Fargo lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $42 from $45 and keeps an...

10h ago

ARCT

Arcturus Therapeutics reports Q2 EPS (34c), consensus (87c)

Reports Q2 revenue $28.3M, consensus $18.7M. Cash, cash equivalents and restricted cash were $253.4 million as of June...

24h ago

ARCT

Private Markets: Canva draws attention as IPO candidate following Figma debut

Canva is gaining significant attention as a potential IPO candidate. The rising investor enthusiasm around the design-software giant...

4d ago

CAI

Optimistic Buy Rating for Arcturus Therapeutics Driven by Promising Developments in Cystic Fibrosis and COVID-19 Vaccine Programs

William Blair analyst Myles Minter has reiterated their bullish stance on ARCT stock, giving a Buy rating on...

11h ago

ARCT

Arcturus Therapeutics Reports Q2 2025 Earnings and Pipeline Progress

Arcturus Therapeutics ( ($ARCT) ) has released its Q2 earnings. Here is a breakdown of the information Arcturus...

16h ago

ARCT

Is ARCT a Buy, Before Earnings?

Arcturus Therapeutics (ARCT) is scheduled to report 2nd quarter earnings on 08/11/2025, after the market closes. Regarding Q2...

3d ago

ARCT

Arcturus Therapeutics: Strategic Focus Beyond mRNA Vaccines Drives Buy Rating

In a report released yesterday, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Arcturus Therapeutics, with...

5d ago

ARCT

Arcturus Therapeutics: Promising mRNA Developments and High Upside Potential Justify Buy Rating

Citi analyst Yigal Nochomovitz has maintained their bullish stance on ARCT stock, giving a Buy rating on July...

28d ago

ARCT

3 Best Stocks to Buy Now, 7/7/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

1M ago

ARCT

Arcturus Therapeutics price target raised to $35 from $32 at Scotiabank

Scotiabank raised the firm’s price target on Arcturus Therapeutics (ARCT) to $35 from $32 and keeps an Outperform...

1M ago

ARCT

Positive Outlook for ARCT-810: Safety and Efficacy Indicators Justify Buy Rating

Leerink Partners analyst Lili (Aurélie) Nsongo has maintained their bullish stance on ARCT stock, giving a Buy rating...

1M ago

ARCT

Positive Outlook for Arcturus Therapeutics: Promising mRNA Technology and Competitive Edge in Urea-Cycle Disorders

Thomas Shrader, an analyst from BTIG, maintained the Buy rating on Arcturus Therapeutics (ARCT – Research Report). The...

1M ago

ARCT

Positive Outlook for Arcturus Therapeutics Amid Promising Developments in ARCT-810 and ARCT-032 Programs

Analyst Whitney Ijem from Canaccord Genuity maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report) and...

1M ago

ARCT

ARCT FAQ

What was Arcturus Therapeutics’s price range in the past 12 months?

Arcturus Therapeutics lowest stock price was $8.04 and its highest was $25.88 in the past 12 months.

What is Arcturus Therapeutics’s market cap?

Arcturus Therapeutics’s market cap is $323.01M.

When is Arcturus Therapeutics’s upcoming earnings report date?

Arcturus Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 85 days.

How were Arcturus Therapeutics’s earnings last quarter?

Arcturus Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.892 by $0.552.

Is Arcturus Therapeutics overvalued?

According to Wall Street analysts Arcturus Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Arcturus Therapeutics pay dividends?

Arcturus Therapeutics pays a Notavailable dividend of $0.06 which represents an annual dividend yield of N/A. See more information on Arcturus Therapeutics dividends here

What is Arcturus Therapeutics’s EPS estimate?

Arcturus Therapeutics’s EPS estimate is -0.85.

How many shares outstanding does Arcturus Therapeutics have?

Arcturus Therapeutics has 27,120,604 shares outstanding.

What happened to Arcturus Therapeutics’s price movement after its last earnings report?

Arcturus Therapeutics reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.892. Following the earnings report the stock price went same N/A.

Which hedge fund is a major shareholder of Arcturus Therapeutics?

Currently, no hedge funds are holding shares in ARCT

Arcturus Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-24.57%

Trailing 12-Months

Asset Growth

-20.79%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Arcturus Therapeutics

Arcturus Therapeutics is a clinical-stage biotechnology company focused on the development of innovative RNA medicines. The company operates primarily in the therapeutic sectors of infectious diseases, rare diseases, and other high unmet medical needs. Arcturus is known for its proprietary LUNAR™ delivery technology, which enables the effective delivery of RNA therapeutics, including mRNA vaccines and therapeutics for diseases such as COVID-19, cystic fibrosis, and various liver disorders.

Arcturus Therapeutics (ARCT) Earnings & Revenues

Historic Earnings Reports

ARCT Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call reflected a balanced outlook, with significant pipeline advancements and strategic focus on mRNA therapeutics leading to an extended cash runway and reduced expenses. However, the revenue decline and net loss present financial challenges. The EU approval of the KOSTAIVE vaccine is a notable achievement, despite conservative expectations for U.S. milestones.View all ARCT earnings summaries

ARCT Stock 12 Month Forecast

Average Price Target

$56.14

▲(392.89% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","141":"$141","41.25":"$41.3","74.5":"$74.5","107.75":"$107.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$140.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$56.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,41.25,74.5,107.75,141],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.3,22.123076923076923,31.946153846153848,41.769230769230774,51.5923076923077,61.415384615384625,71.23846153846154,81.06153846153846,90.88461538461539,100.70769230769231,110.53076923076924,120.35384615384616,130.1769230769231,{"y":140,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.3,15.672307692307694,19.044615384615387,22.416923076923077,25.78923076923077,29.161538461538463,32.533846153846156,35.90615384615385,39.27846153846154,42.650769230769235,46.02307692307693,49.395384615384614,52.767692307692315,{"y":56.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.3,12.353846153846154,12.407692307692308,12.461538461538462,12.515384615384615,12.569230769230769,12.623076923076923,12.676923076923078,12.730769230769232,12.784615384615385,12.838461538461539,12.892307692307693,12.946153846153846,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.58,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.1,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.25,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.64,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.97,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.79,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.81,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.99,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.3,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >